ClinicalTrials.gg
CompletedNCT07486102Updated Nov 12, 2026

A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

A Phase 1 interventional study of BI 3000202 in Healthy and Hepatic Impairment, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is open to healthy people and people with liver problems. Adults between 18 and 80 years can participate. The purpose of this study is to compare how a medicine called BI 3000202 is handled by the body in people with and without liver problems.

All participants take 1 tablet of BI 3000202. Participants with liver problems may also continue their regular treatment for their liver condition.

Participants are in the study for about 1 month. During this time, participants visit the study site about 11 times. Where possible, some of these visits may happen by phone. For some visits, participants stay at the study site overnight. Doctors regularly test the amount of BI 3000202 in the blood and check for any health problems.

02

Conditions studied

  • Healthy
  • Hepatic Impairment
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants ≥18 years and ≤80 years of age at Visit 1.
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to participation in the trial.
  • Male and female participants. Women of must be willing and able to use a highly effective method of per ICH M3 (R2) that results in a low failure rate (i.e. \<1% per year when used consistently and correctly) for the duration of the trial until at least 14 days after drug administration. Throughout the trial and for a period of at least 14 days after medicinal product (IMP) administration, male participants with sexual partners who are women of child-bearing potential must use condoms or practice complete abstinence.
  • (BMI) of 18.5-42.0 kg/m² (inclusive) at Visit 1.

Inclusion criteria Cohort 4 (participants with normal hepatic function)

- Clinically healthy based on medical history, physical examination, vital signs, (ECG), and laboratory tests at Visit 1.

Inclusion criteria Cohorts 1, 2 and 3 (participants with hepatic impairment)

  • Hepatic impairment that meets the criteria for classes A (Cohort 1), B (Cohort 2), or C (Cohort 3).
  • Hepatic decompensation therapies (e.g., diuretics for ascites, lactulose for hepatic encephalopathy, nonselective betablockers for portal hypertension) need to comply with following requirements:

    • No new initiation or permanent discontinuation is permitted within 3 months prior to Visit 1.
    • Major dose modifications (>50% change from baseline) within 4 weeks prior to Visit 1 are exclusionary.
    • Minor titrations consistent with standard clinical management are permitted, provided the investigator confirms that the patient's underlying condition is clinically controlled. Cases involving fluctuating hepatic directed regimens may be included only if both the investigator and the sponsor agree that the patient's clinical condition is controlled and suitable for trial participation.

Exclusion criteria

Exclusion Criteria :

  • Participation in another clinical trial within 30 days or 5 half-lives of the drug (whichever is longer) prior Visit 2.
  • Known to BI 3000202 or any of its .
  • Any documented active or suspected or history of malignancy within 5 years prior to Visit 1 (except appropriately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix (treated >3 years); patients with a remote history of malignancy (≥5 years prior) may be considered and must be discussed with sponsor on a case-by-case basis.
  • Have received stem cell transplantation.
  • Have received live or attenuated vaccination within 8 weeks prior to Visit 2.
  • Have received Bacillus Calmette-Guérin (BCG) vaccines ≤1 year prior to Visit 2.
  • Presence of relevant chronic or acute infections, including active systemic infection requiring antibiotics within 6 weeks prior to Visit 2.
  • Active or latent tuberculosis (TB).

    • Participants with active TB will always be excluded.
    • Participants with latent TB will be excluded if tested positive for Interferon-gamma release assay (IGRA) (QuantiFERON®-TB Gold Plus or T-SPOT®.TB) at Visit 1, not having completed appropriate treatment per local practice/guidelines for TB within the past 3 years and at least 1 month before Visit 2.
    • Participants with indeterminate QuantiFERON®-TB Gold Plus or borderline or invalid T-SPOT®. TB may be retested with IGRA (once) and will be excluded if retesting is inconclusive or positive.
    • Under exceptional circumstances and only after discussion with the sponsor, purified protein derivative (PPD) skin test can be performed if IGRA is not available. A PPD ≥10 mm (≥5 mm if receiving ≥15 mg/day prednisone or other ) is considered positive. Participants with a positive PPD are excluded unless they have completed treatment as above.

Further exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Participants with mild hepatic impairment (Child-Pugh A)

    Drug: BI 3000202

  • Experimental
    Participants with moderate hepatic impairment (Child-Pugh B)

    Drug: BI 3000202

  • Experimental
    Participants with severe hepatic impairment (Child-Pugh C)

    Drug: BI 3000202

  • Experimental
    Participants with normal hepatic function

    Drug: BI 3000202

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

    Time frame: Up to 8 days

  2. Maximum measured concentration of the analyte in plasma (Cmax)

    Time frame: Up to 8 days

Secondary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: Up to 8 days

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Oct 2026, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Feb 2027 → Oct 2026 and completion Feb 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 20, 2026
StartActual
May 1, 2026
Primary completionActual
Oct 30, 2026was Feb 2027
CompletionActual
Oct 31, 2026was Feb 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Feb 26, 2027→Oct 30, 2026 (actual)
Nov 12, 2026
Study completion
Feb 27, 2027→Oct 31, 2026 (actual)
Nov 12, 2026
Enrollment
44 (estimated)→34 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Feb 26, 2027→Oct 30, 2026 (now actual)
    Study completion Feb 27, 2027→Oct 31, 2026 (now actual)
    Enrollment 44 (estimated)→34 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07486102
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
May 1, 2026
Primary completion
Oct 30, 2026
Completion
Oct 31, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 3000202

Start the discussion